-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 RxRh2W0wB4DBYr7zrJzXQMbcBNtL7WsmD6hMLZgIpSyIBZQsmHd6kKyZYQX5xnQw
 wWlDwA+McVKVArxQBstIpQ==

<SEC-DOCUMENT>0000012208-08-000003.txt : 20080228
<SEC-HEADER>0000012208-08-000003.hdr.sgml : 20080228
<ACCEPTANCE-DATETIME>20080228162645
ACCESSION NUMBER:		0000012208-08-000003
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20071231
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20080228
DATE AS OF CHANGE:		20080228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIO RAD LABORATORIES INC
		CENTRAL INDEX KEY:			0000012208
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				941381833
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-07928
		FILM NUMBER:		08651001

	BUSINESS ADDRESS:	
		STREET 1:		1000 ALFRED NOBEL DR
		CITY:			HERCULES
		STATE:			CA
		ZIP:			94547
		BUSINESS PHONE:		5107247000
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k02282008.htm
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>UNITED STATES</TITLE>
<META NAME="author" CONTENT="Tom Brida">
<META NAME="date" CONTENT="02/14/2008">
</HEAD>
<BODY style="line-height:12pt; font-family:Times New Roman; font-size:10pt; color:#000000">
<DIV style="width:643.2px"><P style="margin:0px"><BR></P>
<P style="margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="margin:0px"><BR></P>
<P style="line-height:17.333px; margin:0px; font-size:14.667px" align=center><B>UNITED STATES</B></P>
<P style="line-height:17.333px; margin:0px; font-size:14.667px" align=center><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
<P style="line-height:17.333px; margin:0px; font-size:14.667px" align=center><B>Washington, D.C. 20549</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="line-height:21.333px; margin:0px; font-size:18.667px" align=center><B>FORM 8-K</B></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="line-height:10.667px; margin:0px"><BR></P>
<P style="line-height:17.333px; margin:0px; font-size:14.667px" align=center><B>CURRENT REPORT</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="line-height:17.333px; margin:0px; font-size:14.667px" align=center><B>Date of Report: February 28, 2008</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(Date of earliest event reported)</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="line-height:12px; margin:0px"><BR></P>
<P style="line-height:10.667px; margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-size:18.667px" align=center><B>BIO-RAD LABORATORIES, INC.</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(Exact name of registrant as specified in its charter)</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="margin:0px"><BR></P>
<TABLE style="font-size:13.333px" cellspacing=0 align=center><TR><TD width=360></TD><TD width=7.133></TD><TD width=352.8></TD></TR>
<TR><TD width=719.933 colspan=3><P style="line-height:17.333px; margin:0px; font-size:14.667px" align=center><B>Commission File Number: 1-7928</B></P>
</TD></TR>
<TR><TD width=360><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=7.133><P style="font-size:2pt">&nbsp;</P></TD><TD width=352.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=360><P style="margin:0px; font-size:10.667px">&nbsp;</P>
</TD><TD valign=bottom width=7.133><P style="margin:0px; font-size:10.667px">&nbsp;</P>
</TD><TD width=352.8><P style="margin:0px; font-size:10.667px">&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=360><P style="line-height:17.333px; margin:0px; font-size:14.667px" align=center><B>Delaware</B></P>
</TD><TD valign=bottom width=7.133><P style="margin:0px; font-size:14.667px">&nbsp;</P>
</TD><TD valign=top width=352.8><P style="line-height:17.333px; margin:0px; font-size:14.667px" align=center><B>94-1381833</B></P>
</TD></TR>
<TR><TD valign=top width=360><P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(State or other jurisdiction of</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>incorporation or organization)</B></P>
</TD><TD valign=bottom width=7.133><P style="margin:0px; font-size:10.667px">&nbsp;</P>
</TD><TD valign=top width=352.8><P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(I.R.S. Employer</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>Identification No.)</B></P>
</TD></TR>
<TR><TD valign=top width=360><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=7.133><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=352.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=719.933 colspan=3><P style="line-height:17.333px; margin:0px; font-size:14.667px" align=center><B>1000 Alfred Nobel Dr.</B></P>
<P style="line-height:17.333px; margin:0px; font-size:14.667px" align=center><B>Hercules, California 94547</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(Address of principal executive offices, including zip code)</B></P>
</TD></TR>
<TR><TD valign=top width=360><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=7.133><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=352.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=360><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=7.133><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=352.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=719.933 colspan=3><P style="line-height:17.333px; margin:0px; font-size:14.667px" align=center><B>(510) 724-7000</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(Registrant&#146;s telephone number, including area code)</B></P>
</TD></TR>
</TABLE>
<P style="line-height:10.667px; margin:0px; font-size:10.667px">&nbsp;</P>
<P style="line-height:10.667px; margin:0px"><BR></P>
<P style="line-height:10.667px; margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="line-height:10.667px; margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=28.8></TD><TD width=607.2></TD></TR>
<TR><TD valign=top width=28.8><P style="line-height:13.333px; margin:0px; font-family:Wingdings; font-size:10.667px"><FONT FACE="Wingdings">&#168;</FONT></P>
</TD><TD valign=top width=607.2><P style="line-height:13.333px; margin:0px; font-size:10.667px"><FONT FACE="Times New Roman">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=28.8></TD><TD width=607.2></TD></TR>
<TR><TD valign=top width=28.8><P style="line-height:13.333px; margin:0px; font-family:Wingdings; font-size:10.667px"><FONT FACE="Wingdings">&#168;</FONT></P>
</TD><TD valign=top width=607.2><P style="line-height:13.333px; margin:0px; font-size:10.667px"><FONT FACE="Times New Roman">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=28.8></TD><TD width=607.2></TD></TR>
<TR><TD valign=top width=28.8><P style="line-height:13.333px; margin:0px; font-family:Wingdings; font-size:10.667px"><FONT FACE="Wingdings">&#168;</FONT></P>
</TD><TD valign=top width=607.2><P style="line-height:13.333px; margin:0px; font-size:10.667px"><FONT FACE="Times New Roman">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=28.8></TD><TD width=607.2></TD></TR>
<TR><TD valign=top width=28.8><P style="line-height:13.333px; margin:0px; font-family:Wingdings; font-size:10.667px"><FONT FACE="Wingdings">&#168;</FONT></P>
</TD><TD valign=top width=607.2><P style="line-height:13.333px; margin:0px; font-size:10.667px"><FONT FACE="Times New Roman">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
<P style="margin:0px; page-break-before:always"><B>&nbsp;</B></P>
<P style="margin:0px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=96></TD><TD width=540></TD></TR>
<TR><TD valign=top width=96><P style="margin:0px" align=justify><B>ITEM 2.02</B></P>
</TD><TD valign=top width=540><P style="margin:0px"><B>Results of Operations and Financial Condition</B></P>
</TD></TR>
<TR><TD valign=top width=636 colspan=2><P style="margin-top:4.467px; margin-bottom:0px">On February 28, 2008, Bio-Rad Laboratories, Inc. announced its results of operations and financial condition as of and for the year ended December 31, 2007. &nbsp;A copy of the press release is furnished as Exhibit 99.1 to this report.</P>
</TD></TR>
<TR><TD valign=top width=636 colspan=2><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=636 colspan=2><P style="margin:0px">In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed to be &#147;filed&#148; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. </P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=80.267></TD><TD width=15.733></TD><TD width=540></TD></TR>
<TR><TD valign=top width=80.267><P style="margin:0px"><B>ITEM 9.01</B></P>
</TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=540><P style="margin:0px"><B>Financial Statements and Exhibits</B></P>
</TD></TR>
<TR><TD valign=top width=80.267><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=540><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=80.267><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=540><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=80.267><P style="margin:0px"><B>Exhibit</B></P>
</TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=540><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD style="border-bottom:1px solid #000000" valign=top width=80.267><P style="margin:0px"><B>Number</B></P>
</TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=540><P style="margin:0px"><B>Description</B></P>
</TD></TR>
<TR><TD valign=top width=80.267><P style="margin-top:4.467px; margin-bottom:0px" align=right>99.1&nbsp;</P>
</TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=540><P style="margin-top:4.467px; margin-bottom:0px">Press release of Bio-Rad Laboratories, Inc. dated February 28, 2008</P>
</TD></TR>
</TABLE>
<P style="margin-top:4.467px; margin-bottom:0px"><BR></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><BR>
<BR></P>
<P style="line-height:17.333px; margin:0px; font-size:14.667px; page-break-before:always" align=center><B>SIGNATURES</B></P>
<P style="margin:0px"><BR></P>
<P style="line-height:17.333px; margin:0px; font-size:14.667px">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>
<P style="margin:0px"><BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=50.867></TD><TD width=136.333></TD><TD width=29.467></TD><TD width=29.467></TD><TD width=4></TD><TD width=253.867></TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=257.867 colspan=2><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=257.867 colspan=2><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=287.333 colspan=3><P style="line-height:17.333px; margin:0px; font-size:14.667px">BIO-RAD LABORATORIES, INC.</P>
</TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=257.867 colspan=2><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=50.867><P style="line-height:17.333px; margin:0px; font-size:14.667px">Date:</P>
</TD><TD style="border-bottom:1px solid #000000" width=136.333><P style="line-height:17.333px; margin:0px; font-size:14.667px">February 28, 2008</P>
</TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="line-height:17.333px; margin:0px; font-size:14.667px">By:</P>
</TD><TD style="border-bottom:1px solid #000000" valign=bottom width=257.867 colspan=2><P style="line-height:17.333px; margin:0px; font-size:14.667px">/s/ Christine A. Tsingos</P>
</TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=29.467><P style="margin:0px; font-size:14.667px">&nbsp;</P>
</TD><TD valign=bottom width=4><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=253.867><P style="line-height:17.333px; margin:0px; font-size:14.667px">Christine A. Tsingos<U> </U></P>
</TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=4><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=253.867><P style="line-height:17.333px; margin:0px; font-size:14.667px">Vice President, Chief Financial Officer</P>
</TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=136.333><P style="margin:0px; font-size:14.667px">&nbsp;</P>
</TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=29.467><P style="margin:0px; font-size:14.667px">&nbsp;</P>
</TD><TD valign=bottom width=4><P style="margin:0px; font-size:14.667px">&nbsp;</P>
</TD><TD valign=bottom width=253.867><P style="font-size:2pt">&nbsp;</P></TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<A NAME="id_11"></A><A NAME="id_12"></A><P style="margin:0px"><BR></P>
<P style="line-height:17.333px; margin:0px; font-size:14.667px" align=center><B>EXHIBIT INDEX</B></P>
<P style="margin:0px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=60></TD><TD width=12></TD><TD width=432></TD></TR>
<TR><TD width=60><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=12><P style="margin:0px">&nbsp;</P>
</TD><TD width=432><P style="margin:0px">&nbsp;</P>
</TD></TR>
<TR><TD style="border-bottom:1px solid #000000" valign=bottom width=60><P style="line-height:17.333px; margin:0px; font-size:14.667px">Exhibit</P>
<P style="line-height:17.333px; margin:0px; font-size:14.667px">Number</P>
</TD><TD valign=bottom width=12><P style="margin:0px; font-size:14.667px">&nbsp;</P>
</TD><TD style="border-bottom:1px solid #000000" valign=bottom width=432><P style="line-height:17.333px; margin:0px; font-size:14.667px">Description</P>
</TD></TR>
<TR><TD valign=top width=60><P style="line-height:17.333px; margin:0px; font-size:14.667px" align=right>99.1&nbsp;</P>
</TD><TD valign=bottom width=12><P style="margin:0px; font-size:14.667px">&nbsp;</P>
</TD><TD valign=bottom width=432><P style="line-height:17.333px; margin:0px; font-size:14.667px">Press release of Bio-Rad Laboratories, Inc. dated February 28, 2008</P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
</DIV></BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>exh99112312007.htm
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>PART 1 &#8211; FINANCIAL INFORMATION</TITLE>
<META NAME="author" CONTENT="Stephanie Trudrung">
<META NAME="date" CONTENT="01/24/2008">
</HEAD>
<BODY style="line-height:12pt; font-family:Times New Roman; font-size:10pt; color:#000000">
<DIV style="width:604.8px"><P style="line-height:17.333px; margin:0px; font-size:14.667px" align=right><B><U>Exhibit 99.1</U></B></P>
<P style="margin:0px" align=right><BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=7.2></TD><TD width=603.8></TD><TD width=8.2></TD></TR>
<TR><TD valign=top width=7.2><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=612 colspan=2><P style="line-height:14.667px; margin:0px; padding-right:43.2px; font-family:Arial; font-size:12px"><FONT FACE="Arial"><B><I>FOR IMMEDIATE RELEASE</I></B></FONT></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px" align=center><BR></P>
<P style="line-height:20px; margin:0px; font-family:HelveticaNeueLT Std; font-size:17.333px" align=center><FONT FACE="HelveticaNeueLT Std"><B>BIO-RAD REPORTS FOURTH-QUARTER AND FULL-YEAR </B></FONT></P>
<P style="line-height:20px; margin:0px; font-family:HelveticaNeueLT Std; font-size:17.333px" align=center><B>2007 FINANCIAL RESULTS</B></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std"><B>HERCULES, CA &#150; February 28, 2008 &#150;</B> Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostics products, announced financial results today for the fourth quarter and fiscal year ended December 31, 2007. &nbsp;</P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std">Fourth-quarter revenues were $459.7 million, up 34.0%<FONT COLOR=#0000FF> </FONT>compared to $343.1 million reported for the fourth quarter of 2006.<FONT COLOR=#0000FF> </FONT>This increase was due to a combination of organic growth across Bio-Rad&#146;s two main product areas, the Life Science and Clinical Diagnostics segments, as well as the addition of DiaMed Holding AG products to the Company&#146;s portfolio in the fourth quarter, which resulted in additional revenue of $62.0 million and impacted fourth-quarter and full-year results. Excluding the revenue from the DiaMed acquisition, fourth-quarter revenues were up 15.9%, or 9.0% on a currency-neutral basis, compared to the same quarter last year. </P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std">Net income for the fourth quarter was $12.4 million compared to $16.6 million during the fourth quarter last year. These results reflect non-cash charges of $12.9 million, which includes a one-time charge of $7.7 million for purchased in-process R&amp;D, and approximately $5.2 million in amortization of intangibles related to DiaMed. Including the DiaMed acquisition, fourth-quarter basic earnings from operations were $0.46 per share, or $0.45 per share on a diluted basis, compared to $0.63 and $0.61, respectively, during the same period last year. Fourth-quarter gross margin was 50.8% compared to 54.1% during the same quarter last year. The lower margin in the most recent quarter reflects the impact of the DiaMed acquisition including foregone profit margin and the amortization of intangibles.</P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std">For the full year, sales grew by 14.7% to $1,461.1 million compared to $1,273.9 million in 2006. Excluding revenue from the DiaMed acquisition, Bio-Rad sales grew by 9.8%, or 5.2% after normalizing for the impact of currency effects. Year-over-year net income was $93.0 million, or $3.41 per share on a diluted basis,<FONT COLOR=#0000FF> </FONT>compared to $103.3 million, or $3.83 per share, respectively, in 2006. Full-year gross margin was 54.2% compared to last year&#146;s figure of 55.9%. Revenues, earnings, and gross margin for 2006 were all favorably impacted by one-time additional revenue of $11.7 million which was the result of a licensing settlement agreement reached with bioM&#233;rieux SA in 2006.</P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std">&nbsp;</P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std">&#147;Operationally, 2007 was another year of progress for Bio-Rad and one of investment as we welcomed DiaMed Holding AG into our organization,&#148;<FONT COLOR=#0000FF> </FONT>said Norman Schwartz, Bio-Rad President and Chief Executive Officer. &#147;As 2008 moves forward, we will continue to explore opportunities to expand our business and improve our operational efficiencies.&#148; </P>
<P style="line-height:21.333px; margin:0px; padding-right:43.2px; font-size:16px" align=justify><FONT FACE="Times New Roman">&nbsp;</FONT></P>
<P style="line-height:21.333px; margin:0px" align=justify><BR></P>
<P style="line-height:21.333px; margin:0px; padding-right:43.2px; font-family:HelveticaNeueLT Std" align=center><FONT FACE="HelveticaNeueLT Std">(more)</FONT></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
</TD></TR>
</TABLE>
<P style="margin:0px" align=right><P style="line-height:21.333px; padding-left:0px; padding-top:0px; padding-right:43.2px; padding-bottom:0px; width:0px; font-family:Times New Roman; font-size:13.333px; color:#000000; page-break-before:always"><BR>
<BR></P>
<BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=7.2></TD><TD width=603.8></TD><TD width=8.2></TD></TR>
<TR><TD valign=top width=611 colspan=2><P style="line-height:21.333px; margin:0px; padding-right:43.2px; font-family:HelveticaNeueLT Std; font-size:12px"><B><I>Bio-Rad Reports Fourth-Quarter and Full-Year 2007 Financial Results</I></B></P>
<P style="line-height:14.667px; margin:0px; padding-right:43.2px; font-family:HelveticaNeueLT Std; font-size:12px"><B><I>Page 2</I></B></P>
<P style="margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px" align=justify><BR></P>
<P style="line-height:22.667px; margin:0px; font-family:HelveticaNeueLT Std"><B>Life Science </B></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std">The Life Science segment net sales for the fourth quarter were $184.5 million, up 16.1%<FONT COLOR=#0000FF> </FONT>compared to the same period last year. On a currency-neutral basis, Life Science segment sales increased by<FONT COLOR=#0000FF> </FONT>9.4%<FONT COLOR=#0000FF>. </FONT>Full-year reported revenues for the Life Science segment were $615.1 million,<FONT COLOR=#0000FF> </FONT>up 6.9% over the prior year, or 2.7% on a currency-neutral basis.<FONT COLOR=#0000FF> </FONT>Performance in this segment<FONT COLOR=#0000FF> </FONT>was boosted by sales of the ProteOn<SUP>&#8482; </SUP>protein interaction array system, the Bio-Plex<SUP>&#174;</SUP> suspension array system and reagents, as well as the ProteinChip<SUP>&#174;</SUP> SELDI system. Bio-Plex sales continue to be positively impacted by 57 new assays that were introduced in 2006. Sales of process chromatography media and hardware were strong as the products continued to gain br
oad market acceptance. These materials are used during the purification stages in the manufacture of a variety of pharmaceuticals with a particular applicability to monoclonal antibody-based medicines. Growth in the Life Science segment was negatively impacted by a drop in BSE (bovine spongiform encephalopathy) testing revenues as both the number of animals tested and the average selling price continues to decline. During the fourth quarter, the segment introduced its next generation polymerase chain reaction (PCR) instruments, which are based on the new 1000-series thermal cycling platform, as well as the ProteoMiner<SUP>&#8482; </SUP>protein enrichment kits, which provide researchers a way to concentrate and enrich low-and medium-abundance proteins that cannot be detected through traditional methods. </P>
<P style="margin:0px"><BR></P>
<P style="line-height:22.667px; margin:0px; font-family:HelveticaNeueLT Std"><B>Clinical Diagnostics</B></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std">The Clinical Diagnostics segment reported net sales of $271.4 million<FONT COLOR=#0000FF> </FONT>for the fourth quarter, up 50.7% compared to the prior-year quarter. Excluding revenue from the DiaMed acquisition, net sales were up 16.3%, or 9.0% on a currency-neutral basis, from the same period last year. Full-year reported revenues for the Clinical Diagnostics segment were<FONT COLOR=#0000FF> </FONT>$832.2 million, a 21.5% increase<FONT COLOR=#0000FF> </FONT>compared to<FONT COLOR=#0000FF> </FONT>2006 results. Excluding revenue from the DiaMed acquisition, net sales increased 12.5%, or 7.4% net of currency effects, compared to 2006 results. These results were largely due to continued growth across all product lines, most notably quality controls, autoimmune, diabetes, clinical microbiology, as well as the BioPlex<SUP>&#174; &nbsp;</SUP>2200 system, a revolutionary instrument for the diagnostic laboratory that is continuing to gain 
market acceptance. In October, the Clinical Diagnostics segment finalized the acquisition of DiaMed Holding AG, a Swiss-based company that develops, manufactures, and markets a complete line of reagents and instruments used in blood typing and screening. Also during the quarter, the segment introduced to the U.S. market, the MRSA<I>Select</I><SUP>&#8482;</SUP> test, a chromogenic medium that detects methicillin-resistant <I>Staphylococcus aureus</I>, as well as its in2it<SUP>&#8482; </SUP>analyzer for the &#8220;point-of-care&#8221; diabetes market. The in2it analyzer measures A1C, combining laboratory-accurate test results with patient convenience. &nbsp;</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-family:HelveticaNeueLT Std" align=center>(more)</P>
</TD><TD valign=top width=8.133 colspan=2><P style="font-size:2pt">&nbsp;</P></TD></TR>
</TABLE>
<P style="line-height:21.333px; margin:0px"><P style="line-height:21.333px; padding-left:0px; padding-top:0px; padding-right:43.2px; padding-bottom:0px; width:0px; font-family:Times New Roman; font-size:13.333px; color:#000000; page-break-before:always"><BR></P>
<BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=7.2></TD><TD width=603.8></TD><TD width=8.2></TD></TR>
<TR><TD valign=top width=611 colspan=2><P style="line-height:21.333px; margin:0px; padding-right:43.2px; font-family:HelveticaNeueLT Std; font-size:12px"><B><I>Bio-Rad Reports Fourth-Quarter and Full-Year 2007 Financial Results</I></B></P>
<P style="line-height:14.667px; margin:0px; font-family:HelveticaNeueLT Std; font-size:12px"><B><I>Page 3</I></B></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:22.667px; margin:0px; font-family:HelveticaNeueLT Std"><B>2007 Full Year Highlights</B></P>
<P style="line-height:24px; margin-top:0px; margin-bottom:-24px; padding-left:48px; text-indent:-24px; font-family:Symbol"><FONT FACE="Symbol">&#183;</FONT></P>
<P style="line-height:21.333px; margin:0px; padding-left:48px; font-family:HelveticaNeueLT Std"><FONT FACE="HelveticaNeueLT Std">Full-year Company sales grew by 14.7% to $1,461.1 million. </FONT></P>
<P style="line-height:24px; margin-top:0px; margin-bottom:-24px; padding-left:48px; text-indent:-24px; font-family:Symbol"><FONT FACE="Symbol">&#183;</FONT></P>
<P style="line-height:21.333px; margin:0px; padding-left:48px; font-family:HelveticaNeueLT Std"><FONT FACE="HelveticaNeueLT Std">Year-over-year net income was $93.0 million, compared to $103.3 million reported in 2006.</FONT></P>
<P style="line-height:24px; margin-top:0px; margin-bottom:-24px; padding-left:48px; text-indent:-24px; font-family:Symbol"><FONT FACE="Symbol">&#183;</FONT></P>
<P style="line-height:21.333px; margin:0px; padding-left:48px; font-family:HelveticaNeueLT Std"><FONT FACE="HelveticaNeueLT Std">In October, the Company purchased 86% of the outstanding stock of DiaMed for approximately 477 million Swiss francs. </FONT></P>
<P style="line-height:24px; margin-top:0px; margin-bottom:-24px; padding-left:48px; text-indent:-24px; font-family:Symbol"><FONT FACE="Symbol">&#183;</FONT></P>
<P style="line-height:21.333px; margin:0px; padding-left:48px; font-family:HelveticaNeueLT Std"><FONT FACE="HelveticaNeueLT Std">During the first quarter, the Company introduced a number of new products including the Mini-PROTEAN</FONT><SUP>&#174;</SUP> Tetra cell, Bio-Rad&#146;s fourth generation electrophoresis system, and the Profinia<SUP>&#8482; </SUP>protein purification system. &nbsp;</P>
<P style="line-height:24px; margin-top:0px; margin-bottom:-24px; padding-left:48px; text-indent:-24px; font-family:Symbol"><FONT FACE="Symbol">&#183;</FONT></P>
<P style="line-height:21.333px; margin:0px; padding-left:48px; font-family:HelveticaNeueLT Std"><FONT FACE="HelveticaNeueLT Std">Also during the quarter, the Company introduced new assays for use on its BioPlex 2200 system for the detection of the Epstein Barr Virus as well as three of the most clinically relevant bacteria that cause syphilis. </FONT></P>
<P style="line-height:24px; margin-top:0px; margin-bottom:-24px; padding-left:48px; text-indent:-24px; font-family:Symbol"><FONT FACE="Symbol">&#183;</FONT></P>
<P style="line-height:21.333px; margin:0px; padding-left:48px; font-family:HelveticaNeueLT Std"><FONT FACE="HelveticaNeueLT Std">In the second quarter, the Company signed two multi-year agreements with Quest Diagnostics to place BioPlex 2200 systems and autoimmune test reagents as well as HIV test systems and quality controls in their network of reference laboratories nationwide. In addition, Bio-Rad and Beckman Coulter announced an agreement regarding the continued development and manufacture of immunodiagnostic tests for blood virus and infectious disease.</FONT></P>
<P style="line-height:24px; margin-top:0px; margin-bottom:-24px; padding-left:48px; text-indent:-24px; font-family:Symbol"><FONT FACE="Symbol">&#183;</FONT></P>
<P style="line-height:21.333px; margin:0px; padding-left:48px; font-family:HelveticaNeueLT Std"><FONT FACE="HelveticaNeueLT Std">In September, the Company introduced three new ProteinChip SELDI system qualification and calibration kits that help improve reproducibility during biomarker discovery. </FONT></P>
<P style="line-height:24px; margin-top:0px; margin-bottom:-24px; padding-left:48px; text-indent:-24px; font-family:Symbol"><FONT FACE="Symbol">&#183;</FONT></P>
<P style="line-height:21.333px; margin:0px; padding-left:48px; font-family:HelveticaNeueLT Std"><FONT FACE="HelveticaNeueLT Std">In October, Bio-Rad launched the Gene Pulser MXcell</FONT><SUP>&#8482; </SUP>electroporation system designed for researchers working with mammalian cells. &nbsp;</P>
<P style="line-height:24px; margin-top:0px; margin-bottom:-24px; padding-left:48px; text-indent:-24px; font-family:Symbol"><FONT FACE="Symbol">&#183;</FONT></P>
<P style="line-height:21.333px; margin:0px; padding-left:48px; font-family:HelveticaNeueLT Std"><FONT FACE="HelveticaNeueLT Std">In November, the Company introduced to the U.S. market, the MRSA</FONT><I>Select</I> test, a chromogenic medium used for the rapid screening of MRSA (methicillin resistant <I>Staphylococcus aureus</I>). &nbsp;</P>
<P style="line-height:24px; margin-top:0px; margin-bottom:-24px; padding-left:48px; text-indent:-24px; font-family:Symbol"><FONT FACE="Symbol">&#183;</FONT></P>
<P style="line-height:21.333px; margin:0px; padding-left:48px; font-family:HelveticaNeueLT Std"><FONT FACE="HelveticaNeueLT Std">Also in November, Bio-Rad launched the in2it analyzer for the &#147;point-of-care&#148; diabetes market. The analyzer measures A1C, a well established indicator of a diabetic patient&#146;s glucose control.</FONT></P>
<P style="margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std">Management will discuss these results in a conference call at 2 p.m. Pacific Time (5 p.m. Eastern Time) February 28, 2008. Interested parties can access the call by dialing 800-659-2037 (in the U.S.), or 617-614-2713 (international), access number 75436489. The live webcast can be accessed at <U>http://www.bio-rad.com</U>. A replay of the call will be available at 888-286-8010 (in the U.S.), or 617-801-6888 (international), access number 38553576, for seven days following the call and the webcast can be accessed at <U>http://www.bio-rad.com</U> for 30 days.</P>
<P style="margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std"><B>About Bio-Rad </B></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std">Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its </P>
<P style="line-height:21.333px; margin:0px"><BR></P>
</TD><TD valign=top width=8.133 colspan=2><P style="font-size:2pt">&nbsp;</P></TD></TR>
</TABLE>
<P style="line-height:21.333px; margin:0px"><P style="line-height:21.333px; padding:0px; width:0px; font-family:Times New Roman; font-size:13.333px; color:#000000; page-break-before:always"><BR></P>
<BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=7.2></TD><TD width=603.8></TD><TD width=8.2></TD></TR>
<TR><TD valign=top width=611 colspan=2><P style="line-height:21.333px; margin:0px"><BR></P>
<P style="margin:0px; font-family:HelveticaNeueLT Std" align=center>(more)</P>
<P style="line-height:21.333px; margin:0px; padding-right:43.2px; font-family:HelveticaNeueLT Std; font-size:12px"><B><I>Bio-Rad Reports Fourth-Quarter and Full-Year 2007 Financial Results</I></B></P>
<P style="line-height:14.667px; margin:0px; font-family:HelveticaNeueLT Std; font-size:12px"><B><I>Page 4</I></B></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std">commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs approximately 6,300 people globally and had revenues approaching $1.5 billion in 2007. For more information, visit www.bio-rad.com. </P>
<P style="margin:0px"><BR></P>
<P style="line-height:14.667px; margin:0px; padding-left:24px; padding-right:43.2px; font-family:HelveticaNeueLT Std; font-size:12px; color:#0000FF"><FONT COLOR=#0000FF>&nbsp;</FONT></P>
<P style="line-height:14.667px; margin:0px; font-family:HelveticaNeueLT Std; font-size:12px"><FONT COLOR=#000000><I>This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, &#147;believe,&#148; &#147;expect,&#148; &#147;may,&#148; &#147;will,&#148; &#147;intend,&#148; &#147;estimate,&#148; &#147;continue,&#148; or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the &#147;Risk Factors&#148; in the Company&#146;s public reports filed with the Securities and Exchange Commission, including the Company&#1
46;s Annual Report on Form 10-K for the fiscal year ended December 31, 2006, as updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. &nbsp;Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements</I></FONT>. <FONT COLOR=#0000FF>&nbsp;</FONT></P>
<P style="margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std"><B>For more information contact:</B></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std">Christine Tsingos, Vice President and Chief Financial Officer, or</P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std">Ron Hutton, Treasurer</P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std">Bio-Rad Laboratories, Inc.</P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std">510-724-7000</P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std">investor_relations@bio-rad.com<FONT FACE="Courier New"> </FONT></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; padding-right:43.2px; font-size:16px" align=justify><FONT FACE="Times New Roman">&nbsp;</FONT></P>
</TD><TD valign=top width=8.133 colspan=2><P style="font-size:2pt">&nbsp;</P></TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
<P style="margin:0px; page-break-before:always"><BR></P>
<P style="margin:0px" align=right><BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=319.333></TD><TD width=74.533></TD><TD width=12></TD><TD width=71.667></TD><TD width=12></TD><TD width=77.667></TD><TD width=12.333></TD><TD width=71></TD></TR>
<TR><TD valign=top width=650.533 colspan=8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=650.533 colspan=8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=650.533 colspan=8><P style="line-height:14.667px; margin:0px; font-size:12px" align=center>BIO-RAD LABORATORIES, INC.</P>
</TD></TR>
<TR><TD valign=top width=650.533 colspan=8><P style="line-height:14.667px; margin:0px; font-size:12px" align=center>Condensed Consolidated Statements of Income</P>
</TD></TR>
<TR><TD valign=top width=650.533 colspan=8><P style="line-height:14.667px; margin:0px; font-size:12px" align=center>(In thousands, except per share data)</P>
</TD></TR>
<TR><TD valign=top width=650.533 colspan=8><P style="line-height:14.667px; margin:0px; font-size:12px" align=center>(Unaudited)</P>
</TD></TR>
<TR><TD valign=top width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=158.2 colspan=3><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=12><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=161 colspan=3><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=158.2 colspan=3><P style="line-height:14.667px; margin:0px; font-size:12px" align=center>Three Months Ended</P>
<P style="line-height:14.667px; margin:0px; font-size:12px" align=center>December 31,</P>
</TD><TD valign=top width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=161 colspan=3><P style="line-height:14.667px; margin:0px; font-size:12px" align=center>Twelve Months Ended</P>
<P style="line-height:14.667px; margin:0px; font-size:12px" align=center>December 31,</P>
</TD></TR>
<TR><TD width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=center>2007</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=center>2006</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=center>2007</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=center>2006</P>
</TD></TR>
<TR><TD width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Net sales</P>
</TD><TD width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;459,688&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;343,081&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;1,461,052&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;1,273,930&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Cost of goods sold</P>
</TD><TD style="border-bottom:1px solid #000000" width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>226,055&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>157,524&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>669,690&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>561,394&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Gross profit</P>
</TD><TD width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>233,633&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>185,557&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>791,362&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>712,536&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Selling, general and administrative expense</P>
</TD><TD width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>162,990&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>122,463&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>507,978&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>438,949&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Product research and development expense</P>
</TD><TD width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>39,855&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>33,326&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>140,535&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>123,376&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Purchased in-process research and development expense</P>
</TD><TD width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>7,656&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>4,100&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>7,656&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>4,100&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Interest expense</P>
</TD><TD width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>8,023&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>7,911&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>31,606&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>32,022&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Foreign exchange losses, net</P>
</TD><TD width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>2,989&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>94&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>2,576&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>1,053&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Other income</P>
</TD><TD width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>(464)</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>(6,182)</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>(19,832)</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>(28,991)</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Income before tax and minority interests</P>
</TD><TD style="border-top:1px solid #000000" width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>12,584&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>23,845&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>120,843&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>142,027&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Minority interests in earnings of consolidated subsidiaries</P>
</TD><TD style="border-bottom:1px solid #000000" width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>(1,301)</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>--&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>(1,301)</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>--&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Income before tax</P>
</TD><TD width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>11,283&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>23,845&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>119,542&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>142,027&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Provision (benefit) for taxes</P>
</TD><TD style="border-bottom:1px solid #000000" width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>(1,072)</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>7,196&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>26,548&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>38,764&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Net income</P>
</TD><TD style="border-bottom:2.667px double #000000" width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;12,355&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;16,649&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;92,994&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;103,263&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-top:2.667px double #000000" width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-top:2.667px double #000000" width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-top:2.667px double #000000" width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Basic earnings per share:</P>
</TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; text-indent:19.2px; font-size:12px">Net income</P>
</TD><TD style="border-bottom:2.667px double #000000" width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;0.46&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;0.63&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;3.49&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;3.92&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; text-indent:19.2px; font-size:12px">Weighted average common shares</P>
</TD><TD style="border-bottom:2.667px double #000000" width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>26,780&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>26,478&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>26,684&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>26,376&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Diluted earnings per share:</P>
</TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; text-indent:19.2px; font-size:12px">Net income</P>
</TD><TD style="border-bottom:2.667px double #000000" width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;0.45&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;0.61&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;3.41&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;3.83&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; text-indent:19.2px; font-size:12px">Weighted average common shares</P>
</TD><TD style="border-bottom:2.667px double #000000" width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>27,456&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>27,086&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>27,260&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>26,949&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px" align=center><BR>
<BR></P>
<P style="margin:0px; padding-left:-48px; padding-right:-65.333px; font-size:12px; page-break-before:always" align=center>BIO-RAD LABORATORIES, INC</P>
<P style="margin:0px; font-size:12px" align=center>Condensed Consolidated Balance Sheets</P>
<P style="margin:0px; font-size:12px" align=center>(In thousands)</P>
<P style="margin:0px; font-size:12px" align=center>(Unaudited)</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=415.667></TD><TD width=16.667></TD><TD width=91.4></TD><TD width=17></TD><TD width=90.467></TD></TR>
<TR><TD valign=top width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=91.4><P style="margin:0px; font-size:12px" align=center>December 31,</P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=90.467><P style="margin:0px; font-size:12px" align=center>December 31,</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=91.4><P style="margin:0px; font-size:12px" align=center>2007</P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=90.467><P style="margin:0px; font-size:12px" align=center>2006</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; font-size:12px">Current assets: </P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=91.4><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=90.467><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Cash and cash equivalents</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;161,764&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;223,607&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Short-term investments</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>61,977&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>264,473&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Accounts receivable, net </P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>358,076&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>292,970&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Inventories, net </P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>321,015&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>253,045&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Other current assets</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=91.4><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>126,142&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=90.467><P style="margin:0px; font-size:12px" align=right>95,682&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; text-indent:28.8px; font-size:12px">Total current assets </P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>1,028,974&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>1,129,777&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="font-size:2pt">&nbsp;</P></TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; font-size:12px">Net property, plant and equipment </P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>271,561&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>189,627&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; font-size:12px">Goodwill </P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>328,439&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>119,492&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; font-size:12px">Purchased intangibles, net</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>210,304&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>44,605&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; font-size:12px">Other assets </P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=91.4><P style="margin:0px; font-size:12px" align=right>132,316&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=90.467><P style="margin:0px; font-size:12px" align=right>112,667&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; text-indent:28.8px; font-size:12px">Total assets</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=91.4><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;1,971,594&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=90.467><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;1,596,168&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=91.4><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=90.467><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; font-size:12px">Current liabilities:</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=91.4><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=90.467><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Notes payable and current maturities of long-term debt</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=91.4><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15,627&nbsp;</P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=90.467><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3,042&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Accounts payable</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>96,470&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>83,411&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Accrued payroll and employee benefits</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>121,255&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>92,101&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Sales, income and other taxes payable</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>27,905&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>19,949&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Other current liabilities</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=91.4><P style="margin:0px; font-size:12px" align=right>152,911&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=90.467><P style="margin:0px; font-size:12px" align=right>121,030&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; text-indent:28.8px; font-size:12px">Total current liabilities</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>414,168&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>319,533&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="font-size:2pt">&nbsp;</P></TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; font-size:12px">Long-term debt, net of current maturities</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>441,805&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>425,625&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; font-size:12px">Other long-term liabilities</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>109,497&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>31,472&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; font-size:12px">Minority interests</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>34,434&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>--&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; font-size:12px">Stockholders&#146; equity</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=91.4><P style="margin:0px; font-size:12px" align=right>971,690&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=90.467><P style="margin:0px; font-size:12px" align=right>819,538&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; text-indent:28.8px; font-size:12px">Total liabilities, minority interests and stockholders&#146; equity</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=91.4><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;1,971,594&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=90.467><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;1,596,168&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=91.4><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=90.467><P style="font-size:2pt">&nbsp;</P></TD></TR>
</TABLE>
<P style="line-height:14.667px; margin-top:0px; margin-bottom:6px; font-size:12px">&nbsp;</P>
<P style="margin-top:0px; margin-bottom:6px"><BR>
<BR></P>
<P style="margin-top:0px; margin-bottom:6px; page-break-before:always"><BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=415.667></TD><TD width=84></TD><TD width=24></TD><TD width=84></TD></TR>
<TR><TD valign=top width=607.667 colspan=4><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>BIO-RAD LABORATORIES, INC.</P>
</TD></TR>
<TR><TD valign=top width=607.667 colspan=4><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>Condensed Consolidated Statements of Cash Flows</P>
</TD></TR>
<TR><TD valign=top width=607.667 colspan=4><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>(In thousands)</P>
</TD></TR>
<TR><TD valign=top width=607.667 colspan=4><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>(Unaudited) &nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=192 colspan=3><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=192 colspan=3><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>Twelve Months Ended</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=192 colspan=3><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>December 31,</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=84><P style="line-height:13.333px; margin:0px; font-size:12px" align=right>2007&nbsp;</P>
</TD><TD valign=top width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=84><P style="line-height:13.333px; margin:0px; font-size:12px" align=right>2006&nbsp;</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Cash flows from operating activities:</P>
</TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Cash received from customers</P>
</TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;1,467,626&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;1,247,779&nbsp;</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Cash paid to suppliers and employees</P>
</TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(1,225,968)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(1,058,977)</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Interest paid</P>
</TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(30,588)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(31,049)</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Income tax payments</P>
</TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(38,253)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(16,072)</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Litigation settlement </P>
</TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(4,228)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(46,981)</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Other operating activities</P>
</TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>22,991&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>23,529&nbsp;</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Net cash provided by operating activities</P>
</TD><TD style="border-top:1px solid #000000" width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>191,580&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-top:1px solid #000000" width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>118,229&nbsp;</P>
</TD></TR>
<TR><TD width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Cash flows from investing activities:</P>
</TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Payment for acquisitions, net of cash received, and long-term investments</P>
</TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(387,673)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(46,071)</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Receipt (payment) of restricted cash</P>
</TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>--&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>36,138&nbsp;</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Other investing activities</P>
</TD><TD style="border-bottom:1px solid #000000" width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>133,244&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(197,815)</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Net cash used in investing activities</P>
</TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(254,429)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(207,748)</P>
</TD></TR>
<TR><TD width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Cash flows from financing activities:</P>
</TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; text-indent:19.2px; font-size:12px">Payments on long-term debt</P>
</TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(17,720)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(487)</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; text-indent:19.2px; font-size:12px">Other financing activities</P>
</TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>10,270&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>10,649&nbsp;</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; text-indent:19.2px; font-size:12px">Net cash provided by (used in) financing activities</P>
</TD><TD style="border-top:1px solid #000000" width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(7,450)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-top:1px solid #000000" width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>10,162&nbsp;</P>
</TD></TR>
<TR><TD width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Effect of exchange rate changes on cash</P>
</TD><TD style="border-bottom:1px solid #000000" width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>8,456&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>6,248&nbsp;</P>
</TD></TR>
<TR><TD width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Net decrease in cash and cash equivalents</P>
</TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(61,843)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(73,109)</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Cash and cash equivalents at beginning of period</P>
</TD><TD style="border-bottom:1px solid #000000" width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>223,607&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>296,716&nbsp;</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Cash and cash equivalents at end of period</P>
</TD><TD style="border-bottom:2.667px double #000000" width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;161,764&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;223,607&nbsp;</P>
</TD></TR>
<TR><TD width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin:0px; font-size:12px">Reconciliation of net income to net cash provided by operating activities:</P>
</TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin:0px; font-size:12px">Net income </P>
</TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;92,994&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;103,263&nbsp;</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Adjustments to reconcile net income to net cash provided by&nbsp;</P>
</TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; text-indent:9.6px; font-size:12px">operating activities (net of effects of acquisitions):</P>
</TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; text-indent:19.2px; font-size:12px">Depreciation and amortization</P>
</TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>67,258&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>55,414&nbsp;</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; text-indent:19.2px; font-size:12px">Changes in working capital</P>
</TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>11,038&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(10,270)</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; text-indent:19.2px; font-size:12px">Litigation settlement</P>
</TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(4,228)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(46,981)</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; text-indent:19.2px; font-size:12px">Other</P>
</TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>24,518&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>16,803&nbsp;</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Net cash provided by operating activities</P>
</TD><TD style="border-top:1px solid #000000; border-bottom:2.667px double #000000" width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;191,580&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-top:1px solid #000000; border-bottom:2.667px double #000000" width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;118,229&nbsp;</P>
</TD></TR>
<TR><TD width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
</DIV></BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
